Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Adavosertib

Generic Name: Adavosertib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Overview

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Background

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Phase 1

Recruiting

Posted: 2016/06/24

Sponsor:Gustave Roussy, Canc...

ID:NCT02813135

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Phase 2

Terminated

Posted: 2016/02/23

Sponsor:Samsung Medical Cent...

ID:NCT02688907

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Early Phase 1

Active, not recruiting

Posted: 2016/01/20

Sponsor:M.D. Anderson Cancer...

ID:NCT02659241

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Phase 1

Active, not recruiting

Posted: 2015/11/30

Sponsor:AstraZeneca

ID:NCT02617277

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Phase 1

Completed

Posted: 2015/11/20

Sponsor:AstraZeneca

ID:NCT02610075

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Adavosertib Shows Promise in Uterine Serous Carcinoma Despite Tolerability Challenges

15 days ago

The phase 2b ADAGIO trial demonstrated adavosertib's antitumor activity with a 26% objective response rate in patients with recurrent or persistent uterine serous carcinoma, though median progression-free survival was only 2.8 months.

Schrödinger Unveils Promising Preclinical Data for Novel Cancer Therapeutics at AACR 2025

2 months ago

Schrödinger presented preclinical data for SGR-3515, a Wee1/Myt1 co-inhibitor showing superior anti-tumor activity compared to monotherapy inhibitors, with optimized dosing schedules that preserve efficacy while minimizing side effects.

Phase IIb ADAGIO Trial: Adavosertib Shows Limited Efficacy with High Toxicity in Uterine Serous Carcinoma

4 months ago

The Wee1 inhibitor adavosertib demonstrated modest activity with a 26% objective response rate in patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial.

Eflornithine (Iwilfin) Approved for High-Risk Neuroblastoma to Reduce Relapse Risk

6 months ago

Eflornithine (Iwilfin) is now FDA-approved to reduce the risk of relapse in high-risk neuroblastoma patients who have shown partial response to prior therapies.

Mathematical Model Identifies PARP Inhibitor Resistance Biomarkers in Triple-Negative Breast Cancer

6 months ago

A novel mathematical model was developed to analyze tumor growth dynamics in triple-negative breast cancer (TNBC) patient-derived xenografts treated with olaparib.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy